Aurinia CEO Peter Greenleaf
After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad
Tiny biotech Aurinia Pharmaceuticals is looking to slay a giant in GlaxoSmithKline’s Benlysta — which just scored a big approval in lupus nephritis — with its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.